Latest press releases

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

EnginZyme AB, a deep-tech company whose cell-free biomanufacturing technology...

Oct 25, 2023

EnginZyme News

Five questions on pseudouridine, with Matthew Thompson

Press releases are necessarily short, so we like to go...

Oct 25, 2023

More news

All Article Blog Pressrelease

How we hire rockstars who play well together

Feb 16, 2023

Blog

EnginZyme Selected for the Second Year in a Row for Cleantech Group’s Global Cleantech 100 List of Companies Committed to Taking Action on the Climate Crisis

Jan 12, 2023

Blog

Announcing our Series B round

Dec 19, 2022

Blog

EnginZyme Raises €21 Million in Series B to Accelerate the Commercialisation of Its Cell-Free Biomanufacturing Technology

Dec 19, 2022

Pressrelease

World-leading chemicals manufacturer Eternis starts collaboration with EnginZyme

Nov 07, 2022

Blog

Testing catalysts in flow – the EnginZyme approach

Jul 12, 2022

Blog

1 2 3 4 … 7

Media contact

Karim Engelmark Cassimjee

CEO and co-founder

press@enginzyme.com

Contacts

Stay up to date with our latest news

Latest press releases

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

EnginZyme News

Five questions on pseudouridine, with Matthew Thompson

More news

How we hire rockstars who play well together

EnginZyme Selected for the Second Year in a Row for Cleantech Group’s Global Cleantech 100 List of Companies Committed to Taking Action on the Climate Crisis

Announcing our Series B round

EnginZyme Raises €21 Million in Series B to Accelerate the Commercialisation of Its Cell-Free Biomanufacturing Technology

World-leading chemicals manufacturer Eternis starts collaboration with EnginZyme

Testing catalysts in flow – the EnginZyme approach

Media contact

Karim Engelmark Cassimjee

Media kit

About

Products and services

Contact

Contacts

Stay up to date with our latest news

Latest press releases

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

EnginZyme News

Five questions on pseudouridine, with Matthew Thompson

More news

How we hire rockstars who play well together

EnginZyme Selected for the Second Year in a Row for Cleantech Group’s Global Cleantech 100 List of Companies Committed to Taking Action on the Climate Crisis

Announcing our Series B round

EnginZyme Raises €21 Million in Series B to Accelerate the Commercialisation of Its Cell-Free Biomanufacturing Technology

World-leading chemicals manufacturer Eternis starts collaboration with EnginZyme

Testing catalysts in flow – the EnginZyme approach

Media contact

Karim Engelmark Cassimjee

Media kit

Stay in touch with us. Sign up here for EnginZyme Insights.

Thanks for signing up!

Could not submit form.

Stay in touch with us.
Sign up here for EnginZyme Insights.